Healthcare Realty Trust Inc. - 10-Q Summary (Q2 2025)
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Healthcare Realty Trust Inc. (HR) is a real estate investment trust (REIT) focused on outpatient healthcare properties. As of the reporting date, the Company owned approximately 559 consolidated properties totaling 32.2 million square feet across 32 states, with a gross investment of approximately $11.2 billion. The Company operates as an umbrella partnership REIT, owning 98.6% of the Operating Partnership (OP).
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Total Revenues | $297.5 million | $316.3 million | $596.5 million | $643.1 million |
| Net Loss | $(160.1) million | $(145.9) million | $(205.5) million | $(461.2) million |
| Net Loss (Common Stockholders) | $(157.9) million | $(143.8) million | $(202.7) million | $(454.6) million |
| Diluted EPS | $(0.45) | $(0.39) | $(0.58) | $(1.22) |
| Funds From Operations (FFO) | $120.4 million | $123.8 million | $244.1 million | $10.3 million |
| Normalized FFO | $143.7 million | $143.5 million | $281.5 million | $291.3 million |
| Cash Flow from Operations | N/A | N/A | $211.0 million | $244.3 million |
| Total Debt (Notes & Bonds) | $4.69 billion | N/A | $4.69 billion | $4.66 billion |
| Cash & Equivalents | $25.5 million | N/A | $25.5 million | $68.9 million |
Material Changes vs. Prior Period
- Revenue Decline: Rental income decreased by $21.1 million (6.8%) in Q2 2025 compared to Q2 2024, primarily due to property dispositions ($36.3 million impact) partially offset by leasing activity ($13.4 million increase).
- Impairment Charges: The Company recognized $142.3 million in impairments of real estate properties and credit loss reserves in Q2 2025, compared to $132.1 million in Q2 2024. This includes $125.9 million related to changes in expected holding periods for 13 properties.
- Expense Increases: General and administrative expenses rose by $9.5 million (67.7%) in Q2 2025, driven largely by $10.3 million in restructuring and severance charges.
- Interest Expense: Interest expense decreased by $9.1 million (14.6%) in Q2 2025 due to lower term loan balances and the redemption of Senior Notes due 2025, despite higher rates on the credit facility.
- Dispositions: The Company sold eight properties and two land parcels in the first half of 2025 for a total sales price of $81.2 million, generating net proceeds of $66.8 million.
Guidance, Outlook, and Risks
- Liquidity and Capital: As of June 30, 2025, the Company had $1.2 billion available on its unsecured credit facility. On July 25, 2025, the Company entered into a new credit facility extending the revolver maturity to July 2029.
- Dividends: The Company declared a quarterly dividend of $0.24 per share on July 31, 2025. Dividends for the first half of 2025 were funded by operating cash flows and the credit facility.
- Tenant Risk: Prospect Medical Holdings filed for Chapter 11 bankruptcy in January 2025. The Company leases approximately 80,912 square feet to Prospect, representing $2.9 million in annual revenue. The Company has moved these leases to cash-basis accounting.
- Market Conditions: Rising interest rates and capital market volatility continue to impact the cost of capital and the ability to sell assets or secure joint venture capital.
- Lease Expirations: Approximately 15% of leases are expected to expire annually. There are 722 leases totaling 2.5 million square feet expiring in the remainder of 2025.
Investor Verification Checklist
- Impairment Drivers: Verify the specific properties included in the $125.9 million impairment charge related to "changes in expected holding periods" and the impact on future cash flows.
- Prospect Medical Exposure: Monitor the bankruptcy proceedings of Prospect Medical Holdings and the likelihood of recovering unpaid rent or lease obligations.
- Debt Maturity Profile: Review the new credit facility terms and the schedule of debt maturities, particularly the extension options exercised in Q2 2025.
- Restructuring Costs: Assess the one-time nature of the $10.3 million restructuring and severance charges and their impact on future operating expenses.
- Same-Store NOI: Analyze the Same-Store Cash NOI growth of 4.0% ($325.8 million vs. $313.1 million) to gauge core portfolio performance excluding dispositions and impairments.